Nathan Robison, MD, presents a case of a 14-year-old male with a progressive hypothalamic low-grade glioma whose newly identified KIAA1549::BRAF fusion informs consideration of next-line treatment options after years of relative stability.
Matthew Cascio, DO, reviews second-line treatment for a case of BRAF V600E-mutated recurrent or refractory pediatric low-grade glioma, following initial combination treatment with dabrafenib and trametinib.
Sameer Farouk Sait, MBBS, reviews a case of focal BRAF fusion–positive pediatric low-grade brainstem glioma that initially responded to chemotherapy but later recurred, prompting molecularly guided targeted therapy complicated by treatment-related toxicities.
Nicholas Whipple, MD, MPH, reviews a case of extensive pediatric optic pathway glioma with progression on chemotherapy and MEK inhibition, highlighting the role of molecular testing, BRAF/MEK-targeted therapy, and considerations for treatment selection at recurrence.
Mohamed Shebl Abdelbaki, MD, presents a case of a 9-year-old girl with unresectable BRAF V600E–mutant thalamic pilocytic astrocytoma who experienced severe pyrexia and treatment intolerance on dabrafenib plus trametinib, prompting consideration of alternative therapeutic options.
Matthew Cascio, DO, presents a case of a 3-month-old infant with a bilateral optic pathway glioma that progressed on frontline carboplatin and was subsequently found to be a BRAF V600E–mutated pilocytic astrocytoma.
Lindsey Hoffman, DO, presents a case of a 10-year-old girl with an unresectable BRAF V600E–mutated brainstem ganglioglioma causing obstructive hydrocephalus and visual symptoms, highlighting treatment considerations when further surgical resection is not feasible.
Ashley Margol, MD, MS, presents a case of a 7-year-old girl with a KIAA1549-BRAF fusion–positive pilocytic astrocytoma that remained stable during and after carboplatin-vincristine therapy before progressing nearly 2 years later with new neurologic symptoms requiring additional treatment.
Mohamed Shebl Abdelbaki, MD, presents a case of a 1-year-old boy with a KIAA1549-BRAF fusion–positive brainstem ganglioglioma that demonstrated significant radiographic progression after 3 months of carboplatin and vincristine therapy, prompting consideration of alternative treatment strategies.
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
